These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27481879)

  • 21. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous golimumab therapy for ulcerative colitis.
    Lowe AW; Moseley RH
    Gastroenterology; 2014 Jan; 146(1):1-2. PubMed ID: 24501748
    [No Abstract]   [Full Text] [Related]  

  • 23. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
    Renna S; Mocciaro F; Ventimiglia M; Orlando R; Macaluso FS; Cappello M; Fries W; Mendolaro M; Privitera AC; Ferracane C; Pisana V; Magnano A; Pluchino D; Inserra G; Scarpulla G; Garufi S; Carroccio A; Siringo S; Di Mitri R; Cottone M; Orlando A
    Dig Liver Dis; 2018 Dec; 50(12):1292-1298. PubMed ID: 30007516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
    Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
    Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
    J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on anti-TNF agents in ulcerative colitis.
    Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
    Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
    Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
    Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Still in pursuit.
    Hanauer SB
    Gastroenterology; 2014 Jan; 146(1):13-5. PubMed ID: 24287301
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-tumor necrosis factor therapy for ulcerative colitis.
    Kountouras J; Zavos C; Chatzopoulos D
    Gastroenterology; 2005 Sep; 129(3):1138-9. PubMed ID: 16143158
    [No Abstract]   [Full Text] [Related]  

  • 30. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab for ulcerative colitis.
    Shields CJ; Winter DC
    N Engl J Med; 2006 Mar; 354(13):1424-6; author reply 1424-6. PubMed ID: 16571891
    [No Abstract]   [Full Text] [Related]  

  • 32. Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials.
    Rutgeerts P
    Am J Gastroenterol; 2002 Oct; 97(10):2488-9. PubMed ID: 12385428
    [No Abstract]   [Full Text] [Related]  

  • 33. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.
    Iborra M; García-Morales N; Rubio S; Bertoletti F; Calvo M; Taxonera C; Boscá-Watts MM; Sierra M; Mancenido N; Beltrán B; Nantes Castillejo Ó; García-Planella E; Vera I; Alba C; Martí-Aguado D; Ballester MP; Cano-Sanz N; Pajares-Villarroya R; Cerrillo E; Cañada A; Nos P
    Sci Rep; 2020 Oct; 10(1):17774. PubMed ID: 33082359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease.
    Roblin X; Paul S
    Aliment Pharmacol Ther; 2015 Jul; 42(2):240. PubMed ID: 26081687
    [No Abstract]   [Full Text] [Related]  

  • 35. [Anti-TNF-alpha therapy in ulcerative colitis].
    Lakatos PL; Lakatos L
    Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study.
    Berger AE; Duru G; de Vries A; Marini JC; Aoucheta D; Cornillie F; Nancey S; Detrez I; Gils A; Roblin X; Paul S
    Ther Drug Monit; 2019 Aug; 41(4):459-466. PubMed ID: 30817702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of ulcerative colitis.
    Blonski W; Buchner AM; Lichtenstein GR
    Curr Opin Gastroenterol; 2014 Jan; 30(1):84-96. PubMed ID: 24285003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
    Gies N; Kroeker KI; Wong K; Fedorak RN
    Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.